Hypoxic Gene Expression Signature as a Predictor of Recurrence and Mortality in Early-Stage Non–Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy
JCO Precision Oncology · 2025
DOI: 10.1200/po-24-00659 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Nicholas J Eustace und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Emory University, Atlanta, GA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Radiosurgery, Lung Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Recurrence occurs in 20%-30% of early-stage non–small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). Hypoxia in the tumor microenvironment drives radiation resistance, immune evasion, and tumor progression. Biomarkers measuring hypoxia may be useful for prognostication of NSCLC treated with SBRT. We investigate an RNA-based approach to measure tumor hypoxia and associate these molecular biomarkers with clinical outcomes after SBRT. METHODS We included patients with T1-3N0 NSCLC treated with SBRT. RNA isolated from formalin-fixed paraffin-embedded tumor biopsy specimens (pretreatment) was analyzed using the Clariom-D assay. Hypoxia scores were derived using three well-established gene signatures measuring hypoxia and risk scores were median-dichotomized. Kaplan-Meier and Cox proportional hazards were used to study the association between high hypoxia scores and tumor recurrence and survival. RESULTS We included 92 patients treated between 2008 and 2018 with a median follow-up of 23.9 months. All three signatures were associated with squamous histology ( P < .001) and clinical outcomes, with the Lane signature serving as the most prognostic of disease recurrence and mortality. On multivariable analysis, the Lane signature was associated with worse local recurrence (hazard ratio [HR], 13.36 [95% CI, 1.09 to 163.94]; P = .043), distant recurrence (HR, 2.15 [95% CI, 1.25 to 3.70]; P = .005), disease-free survival (HR, 3.68 [95% CI, 1.41 to 9.58]; P = .008), and overall mortality (HR, 2.91 [95% CI, 1.41 to 9.58]; P = .009). No significant difference was seen in regional nodal recurrence ( P = .277). CONCLUSION We demonstrate squamous histology is associated with RNA-based hypoxic gene signatures, and that the Lane RNA-based hypoxia signature is highly prognostic of disease progression and mortality in NSCLC treated with SBRT, which merits prospective validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Emory University, Atlanta, GA.
- Department of Biomedical Informatics, The Ohio State University, Columbus, OH.
- Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH.
- Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC.
- Department of Radiation Oncology, The Ohio State University, Columbus, OH.
ORCID-Profile: Nicholas J Eustace, Ryan Robb, Arya Amini, Terence M Williams
Förderung
- NCI NIH HHS
Zitieren
APA
Eustace, N. J., Sebastian, N. T., Webb, A., Shilo, K., Robb, R., Amini, A., Yang, L., Denko, N. C., & Williams, T. M. (2025). Hypoxic Gene Expression Signature as a Predictor of Recurrence and Mortality in Early-Stage Non–Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy. JCO Precision Oncology. https://doi.org/10.1200/po-24-00659
Vancouver
Eustace NJ, Sebastian NT, Webb A, Shilo K, Robb R, Amini A, et al. Hypoxic Gene Expression Signature as a Predictor of Recurrence and Mortality in Early-Stage Non–Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy. JCO Precision Oncology. 2025. doi:10.1200/po-24-00659
BibTeX
@article{Eustace2025,
author = {Eustace, Nicholas J and Sebastian, Nikhil T and Webb, Amy and Shilo, Konstantin and Robb, Ryan and Amini, Arya and Yang, Linlin and Denko, Nicholas C and Williams, Terence M},
title = {Hypoxic Gene Expression Signature as a Predictor of Recurrence and Mortality in Early-Stage Non–Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy},
journal = {JCO Precision Oncology},
year = {2025},
doi = {10.1200/po-24-00659}
}
EUVIMED